I am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy .Novo brought in 65.3 billion Danish kroner in net sales during the first three months of 2024, up around 22% from the same period last year.Novo’s diluted earnings per share of 5.
Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts.Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines.
Wegovy Ozempic Semaglutide Ozempic
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicThe agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Baca lebih lajut »
FTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicThe agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Baca lebih lajut »
US Senate committee investigates pricing of Novo's Ozempic and WegovyUS Senate committee investigates pricing of Novo's Ozempic and Wegovy
Baca lebih lajut »
US Senate committee investigates pricing of Novo's Ozempic and WegovyA U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
Baca lebih lajut »
Ozempic maker fires back at Bernie Sanders over claim that the weight loss drug company 'ripped off' AmericansOzempic maker Novo Nordisk is disputing Sen. Bernie Sanders' claim that the weight loss drug can be produced for Americans at a fraction of its current price.
Baca lebih lajut »